Get the Stockscreener App
4.05
0.50%
0.02
Galectin Therapeutics Inc stock is traded at $4.05, with a volume of 412.80K.
It is up +0.50% in the last 24 hours and down -29.69% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$4.03
Open:
$4.05
24h Volume:
412.80K
Relative Volume:
0.88
Market Cap:
$261.11M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-5.5479
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
-7.53%
1M Performance:
-29.69%
6M Performance:
+72.34%
1Y Performance:
+365.46%
1-Day Range:
$3.90
$4.1899
1-Week Range:
$3.53
$4.4186
52-Week Range:
$0.901
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.05 | 259.83M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains - Seeking Alpha
Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock By Investing.com - Investing.com Nigeria
Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares By Investing.com - Investing.com South Africa
Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares - Investing.com Australia
Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares By Investing.com - Investing.com South Africa
Galectin therapeutics director Kevin Freeman buys $19,514 in stock By Investing.com - Investing.com Nigeria
Galectin therapeutics director Kevin Freeman buys $19,514 in stock - Investing.com
Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares - Investing.com
Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 By Investing.com - Investing.com Nigeria
Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 - Investing.com
Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock - Investing.com
Galectin Therapeutics Director Kevin D Freeman Acquires 5,500 Shares - TradingView — Track All Markets
Why did GALT shares plummet over 30% today? - MSN
Galectin Advances Belapectin Program With FDA Feedback And Secures $10 Million Credit Line - Nasdaq
Galectin Therapeutics Earnings Notes - Trefis
Galectin Therapeutics (GALT) Price Target Increased by 83.33% to 11.22 - Nasdaq
Why Galectin Therapeutics Inc. stock is favored by pension fundsJuly 2025 Snapshot & Weekly Top Gainers Trade List - Улправда
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) Insider Sells 19,442 Shares of Stock - MarketBeat
Joel Lewis Sells 7,829 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Director Harold Shlevin Sells 24,499 Shares - MarketBeat
Galectin Therapeutics Executives Sell Shares - TradingView — Track All Markets
FDA provides feedback on Galectin’s belapectin development program By Investing.com - Investing.com Nigeria
Galectin Therapeutics (GALT) Shares Drop After FDA Update and Ne - GuruFocus
Galectin falls on MASH candidate belapectin update, additional $10M credit line - Seeking Alpha
Galectin Shares Fall After FDA Raises Issues With Belapectin Program - marketscreener.com
Why Did GALT Shares Plummet Over 30% Today? - Asianet Newsable
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Galectin Therapeutics stock plummets after FDA feedback on drug By Investing.com - Investing.com Nigeria
Galectin Therapeutics stock plummets after FDA feedback on drug - Investing.com India
Galectin Therapeutics enters line of credit agreement - marketscreener.com
Galectin Therapeutics (GALT) Aligns with FDA on Belapectin Trial - GuruFocus
Galectin Therapeutics provides regulatory update following FDA written response - marketscreener.com
FDA provides feedback on Galectin’s belapectin development program - Investing.com India
Galectin Advances Belapectin Program, Secures New Insider Financing - TipRanks
Galectin advances belapectin program, secures new insider financing - MSN
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 - The Manila Times
Galectin Therapeutics Receives FDA Feedback on Belapectin Development Program and Secures $10 Million Financing - Quiver Quantitative
Galectin Therapeutics Signs Supplemental Line of Credit Agreement With Richard E. Uihlein - TradingView — Track All Markets
New funding keeps potential liver cirrhosis treatment on track to 2027 - Stock Titan
GALT (Galectin Therapeutics) EV-to-OCF : -16.64 (As of Dec. 19, 2025) - GuruFocus
Will Galectin Therapeutics Inc. stock benefit from automation2025 Market WrapUp & Accurate Entry/Exit Alerts - DonanımHaber
What dividend safety score for Galectin Therapeutics Inc. stockJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - DonanımHaber
Will Galectin Therapeutics Inc. stock see insider buyingPortfolio Update Summary & Weekly Breakout Stock Alerts - DonanımHaber
Should I hold or sell Galectin Therapeutics Inc. stock in 20252025 Top Decliners & Verified Momentum Stock Ideas - Улправда
Bull Bear: Should I hold or sell Galectin Therapeutics Inc. stock in 2025Weekly Profit Summary & Technical Pattern Based Buy Signals - Улправда
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):